Literature DB >> 31103467

Targeting neutrophil extracellular traps enhanced tPA fibrinolysis for experimental intracerebral hemorrhage.

Qiang Tan1, Peiwen Guo1, Jiru Zhou1, Jianbo Zhang1, Bo Zhang1, Chuan Lan1, Jishu Xian1, Miandi Ge2, Hua Feng3, Zhi Chen4.   

Abstract

The minimally invasive surgery plus fibrinolysis has been identified as a promising treatment for spontaneous intracerebral hemorrhage (ICH). However, the fibrinolytic efficacy is not satisfactory. Neutrophil extracellular traps (NETs) have been demonstrated to impair fibrinolysis in sepsis and acute ischemic stroke. Therefore, we decided to explore the presence and potential effect of NETs in ICH fibrinolysis. Intracerebral hemorrhage was induced by autologous arterial blood injection into the basal ganglia in rats. First, at 0.5 hour, 1 hour, and 1.5 hours after blood injection, the brains were collected for NETs detection by immune-staining. Second, ICH rats were given intrahematoma fibrinolysis: rats were randomized to receive the equal amount of saline, DNAse 1, tissue-plasminogen activator (tPA), and tPA + DNAse 1 at 1 hour after hematoma placement. On day 3, animals were sacrificed for terminal deoxynucleotidyl transferase-mediated dUTP Nick-end labeling staining following MRI and behavioral tests. Third, on day 3 after ICH, the hematoma within brain were collected for ex vivo fibrinolysis assay to further evaluate the effect of NETs in ICH fibrinolysis. Co-staining of DAPI, H3, and MPO confirmed the presence of NETs in ICH. Disintegration of NETs using DNAse 1 enhanced tPA-induced hematoma fibrinolysis, relieved brain swelling, reduced cell death, and improved the functional outcome in ICH rats. Therefore, we concluded that NETs impaired the efficacy of tPA for ICH fibrinolysis in rats. Targeting NETs may be a new alternative to improve the fibrinolytic therapy following ICH.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31103467     DOI: 10.1016/j.trsl.2019.04.009

Source DB:  PubMed          Journal:  Transl Res        ISSN: 1878-1810            Impact factor:   7.012


  6 in total

1.  Neutrophil Extracellular Traps (NETs): A New Therapeutic Target for Neuroinflammation and Microthrombosis After Subarachnoid Hemorrhage?

Authors:  Jiru Zhou; Peiwen Guo; Xiaoke Hao; Xiaochuan Sun; Hua Feng; Zhi Chen
Journal:  Transl Stroke Res       Date:  2022-06-11       Impact factor: 6.800

2.  Neutrophil Extracellular Traps Exacerbate Secondary Injury via Promoting Neuroinflammation and Blood-Spinal Cord Barrier Disruption in Spinal Cord Injury.

Authors:  Zhou Feng; Lingxia Min; Liang Liang; Beike Chen; Hui Chen; Yi Zhou; Weiwei Deng; Hongliang Liu; Jingming Hou
Journal:  Front Immunol       Date:  2021-08-11       Impact factor: 7.561

3.  Recombinant CCL17 Enhances Hematoma Resolution and Activation of CCR4/ERK/Nrf2/CD163 Signaling Pathway After Intracerebral Hemorrhage in Mice.

Authors:  Shuixiang Deng; Prativa Sherchan; Peng Jin; Lei Huang; Zachary Travis; John H Zhang; Ye Gong; Jiping Tang
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

4.  Neutrophil Extracellular Traps may be a Potential Target for Treating Early Brain Injury in Subarachnoid Hemorrhage.

Authors:  Hanhai Zeng; Xiongjie Fu; Jing Cai; Chenjun Sun; Mengyan Yu; Yucong Peng; Jianfeng Zhuang; Jingyin Chen; Huaijun Chen; Qian Yu; Chaoran Xu; Hang Zhou; Yang Cao; Libin Hu; Jianru Li; Shenglong Cao; Chi Gu; Feng Yan; Gao Chen
Journal:  Transl Stroke Res       Date:  2021-04-14       Impact factor: 6.829

Review 5.  Major histocompatibility complex Class II-based therapy for stroke.

Authors:  Bella M Gonzales-Portillo; Jea-Young Lee; Arthur A Vandenbark; Halina Offner; Cesario V Borlongan
Journal:  Brain Circ       Date:  2021-03-30

Review 6.  The Role of Neutrophil Extracellular Traps in Central Nervous System Diseases and Prospects for Clinical Application.

Authors:  Yinghan Guo; Hanhai Zeng; Chen Gao
Journal:  Oxid Med Cell Longev       Date:  2021-07-13       Impact factor: 6.543

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.